We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Okyo Pharma Limited | OKYO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 91.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 91.00 |
| Industry Sector |
|---|
| MINING |
| Top Posts |
|---|
Posted at 04/4/2023 21:19 by faraweigh2 On NASDAQ maybe tick thwat?NASDAQ will underpin Market Cap and OKYO will indeed go stratospheric. Hardly rocket science ffs.Doh |
Posted at 04/4/2023 15:31 by faraweigh2 lol!!Read the RNS detail as all is quite clear.Onwards and upwards is the way for the Market Cap here at Okyo. Fact. |
Posted at 04/4/2023 08:08 by babbler Not a surprise. UK investors don't get OKYO. |
Posted at 01/4/2023 08:46 by faraweigh2 Just look at the 1 and 5 day OKYO trading summary charts on NASDAQ. Awesome! |
Posted at 16/3/2023 11:22 by bibs OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website."We are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs" said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd. |
Posted at 13/3/2023 15:49 by bibs Okyo CEO states:"2023 is going to be a big year for us!"Shareholder value to be added here... |
Posted at 23/2/2023 07:45 by bibs Absolutely fantastic news for Okyo.Onwards and upwards! |
Posted at 22/2/2023 12:51 by faraweigh2 Okyo set to 'outperform '.Being given a high technical rating as above over on NASDAQ. Please do your own research. |
Posted at 20/2/2023 15:03 by faraweigh2 .... and so the BS starts again lol.By now folk will form their own opinions on who knows their OKYO facts.The thread below tells the story. |
Posted at 13/1/2023 11:23 by faraweigh2 Requoted in part from S/T:OKYO Pharma (OKYO): 2.75p Target 7p A problem with the bear market in small caps is that some timelines have been stretched, as well as valuations kept a lid on until companies are much further down the line as far as their milestones. A good example of both delayed market response and depressed share price is dry eye treatment group OKYO. Of course, it may be the case that even after the latest announcement of clearance of its Investigational New Drug (IND) application from the FDA to initiate a Phase 2 human clinical study. What the market has perhaps still not cottoned onto are a few factors here with OKYO. The dry eye treatment market is a multi-billion dollar one, with the jump in technology with OK-101 which is a treatment, rather than current applications which mere address the symptoms of dry eyes in a mechanical way. Just as important is that because OK-101 is a topical treatment it will have accelerated FDA approval, a point underlined by this month’s news from the company. Such an accelerated approved clearly means that the costs of development are that much more economic. Finally, given the way that the market cap is back to where it was two years ago, despite the advances made, we could see a realignment in 2023, especially given the drug will be “moving into the clinic in the first quarter of 2023"? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
